Sign inJoin waitlistJoin the waitlist

PM

Peter Maslak

Physician · Roswell Park Comprehensive Cancer Center

Credentials: · · · · ·

History

Roswell Park Comprehensive Cancer Center
2023–Present

Hematology and Medical Oncology
1987–1990
Internal Medicine
1984–1987
Icahn School of Medicine at Mount Sinai
1980–1984

Research

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
New England Journal of Medicine · 2018 · 2,239 citations
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia
Science Translational Medicine · 2014 · 2,062 citations
CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia
Science Translational Medicine · 2013 · 1,696 citations

DS
David Scheinberg
23 papers
Joseph Jurcic
15 papers
MT
Martin Tallman
9 papers
JP
Jae Park
8 papers · 1 as a fellow
Renier Brentjens
8 papers
MF
Mark Frattini
7 papers
RW
Raymond Warrell
7 papers
DD
Dan Douer
6 papers
Marco Davila
6 papers · 1 as a fellow
AZ
Andrew Zelenetz
5 papers
DK
David Kelsen
5 papers
Frederick Appelbaum
5 papers

Grants

Inhibition of Histone Deacetylase as Anti Cancer Therapy
National Cancer Institute · R01
Contact PI · $517.9K · Sloan-Kettering Inst Can Research
1999–2004

Clinical trials

WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)
Principal investigator · Completed · Phase 2
Sellas Life Sciences Group
2011–2016
Tretinoin and Arsenic Trioxide With or Without Idarubicin in Treating Patients With Acute Promyelocytic Leukemia
Principal investigator · Terminated · Phase 2
Memorial Sloan Kettering Cancer Center
2007–2011
Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-small Cell Lung Cancer, or Prostate Cancer
Study chair · Completed · Phase 2
Memorial Sloan Kettering Cancer Center
2000–2003
Radiolabeled Monoclonal Antibody Therapy and Etoposide Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Myelodysplastic Syndrome or Refractory Leukemia
Study chair · Completed · Phase 1
Memorial Sloan Kettering Cancer Center
2000–2003